We hypothesized that higher SLC22A3 expression in cancer cells may enhance the uptake of cisplatin after cisplatin treatment and, in turn, reduce the survival of cancer cells, and the opposite may hold true for cancer cells with lower SLC22A3 expression. Here, SLC22A3 is linked to cancer.